紫杉醇联合替吉奥治疗蒽环类耐药晚期乳腺癌患者的疗效及安全性评价  

Evaluation of Efficacy and Safety of Paclitaxel Combined With S-1 for Advanced Breast Cancer Patients with Anthracycline-Resistance

作　　者：何志惠[1] 陈喜 卢彦达[1] 曾江正[1] HE Zhihui;CHEN Xi;LU Yanda;ZENG Jiangzheng(Department of Oncology,the First Affiliated Hospital of Hainan Medical University,Haikou,Hainan,570102,China;Technical Medical Centre of Hainan Medical University,Haikou,Hainan,570102,China)

机构地区：[1]海南医学院第一附属医院肿瘤科,海南海口570102 [2]海南医学院技能中心,海南海口570102

出　　处：《肿瘤药学》2019年第4期653-657,共5页Anti-Tumor Pharmacy

基　　金：海南省重点研发科技合作项目（ZDYF2017165）

摘　　要：目的探讨紫杉醇联合替吉奥治疗蒽环类耐药晚期乳腺癌患者的疗效及安全性。方法选取2014年4月-2018年4月我院收治的蒽环类耐药晚期乳腺癌患者120例为研究对象,采用随机数字表法分为对照组和观察组,各60例。对照组患者采用紫杉醇单药方案进行二线治疗,观察组患者在对照组的基础上联合替吉奥治疗。比较两组患者的近期疗效、血清学指标、中位总生存期(OS)、中位无进展生存期(PFS)、不良反应和生活质量。结果观察组患者疾病控制率(DCR)(80.0%)明显高于对照组(60.0%)(P<0.05);两组患者治疗后血清CA125、CA153及CEA水平均显著降低(P<0.05),且观察组降低更明显(P<0.05);观察组患者白细胞减少发生率显著高于对照组(70.0%vs.46.7%,P<0.05),食欲减退发生率显著高于对照组(56.7%vs.36.7%,P<0.05);观察组患者生活质量改善情况明显优于对照组(P<0.05);观察组患者中位OS和中位PFS均较对照组明显延长(P<0.05)。结论紫杉醇联合替吉奥对蒽环类耐药晚期乳腺癌患者的疗效较好,可明显提高远期生存率,且不良反应可耐受,安全性较高。Objective To investigate the efficacy and safety of paclitaxel combined with S-1 in the treatment of anthracycline-resistant advanced breast cancer.Methods Sixty patients with anthracycline-resistant advanced breast cancer treated in our hospital between April 2014 and April 2018 were selected as the study subjects.Random number table method was used to divide the patients into control group and observation group,with 60 cases in each group.The patients in control group received second-line treatment with paclitaxel monotherapy.While those in observation group were treated with paclitaxel combined with S-1.The short-term efficacy,serological indicators,adverse reactions and quality of life,median overall survival(OS)and median progression-free survival(PFS)of the patients were recorded and compared.Results The disease control rate(DCR)of the observation group was significantly higher than that of the control group(80.0%vs.60.0%,P<0.05).After treatment,the levels of serum CA125,CA153 and CEA in both groups were significantly decreased(P<0.05),and the decrease was greater in observation group than in control group(P<0.05).The incidence of leukopenia in observation group was higher than in control group(70.0%vs.46.7%,P<0.05),and so was the incidence of anorexia(56.7%vs.36.7%,P<0.05).The improvement of life quality of observation group was greater than that of the control group(P<0.05).The median OS and PFS were significantly longer in observation group than in the control group(P<0.05).Conclusion Paclitaxel combined with S-1 has good effects on advanced breast cancer patients with anthracycline resistance.It could improve the quality of life of patients,and its adverse reactions are tolerable,so it is worthy of clinical application.

关 键 词：紫杉醇 替吉奥 蒽环类药物 晚期乳腺癌 疗效 

分 类 号：R737.9[医药卫生—肿瘤]